secwatch.observer — SEC 8-K summary
======================================

Issuer:     KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)
CIK:        0001877184
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-274183
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kestra's ASSURE wearable defibrillator achieves 100% conversion in largest real-world study
--------------------------------------------------------------------------------

- 21,612-patient ACE-PAS trial met primary effectiveness endpoint: 100% successful conversion for VT/VF events.
- Inappropriate-shock rate of 0.0065 per patient-month, below prespecified safety performance goal.
- 94% of patients experienced no false positive shock alarms; median wear time >23 hours per day.
- 2.6% of patients had at least one life-threatening VT/VF event, highlighting early risk.
- Results presented as late-breaking science at AHA Scientific Sessions 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1877184/000119312525274183/0001193125-25-274183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1877184/000119312525274183/ck0001877184-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-274183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer